Mark Cole writes about quality and regulatory compliance in medical device manufacturing. Cole's posts connect FDA warning letters and ISO 13485 requirements to practical decisions, including how manufacturers should validate automated processes and oversee AI-generated documents.
Mark Cole is most useful for explaining medical device quality and regulatory compliance through FDA warning letters and ISO 13485.
Best for
A medical device manufacturer strengthening quality compliance, preparing for FDA inspection, or governing AI in documentation.
Not for
A direct-to-consumer wellness brand or general AI productivity brand seeking large-scale consumer awareness.
Key takeaways
AI can write compliance documents, but a qualified person still owns them.
Automated inspection needs validation, guardrails, and a human backstop.
Quality leadership is a competence question that FDA inspections actually test.
Check first: Confirm audience breakdown, recent performance data, rates, and a direct inquiry route.
Main ideas
AI can write the documents, but a qualified person still owns them · Automated inspection is fine only with validation, guardrails, and a human backstop · Quality leadership is a competence question that inspections actually test
Mark Cole writes about quality and regulatory compliance in medical-device manufacturing.
Their posts turn FDA warning letters and ISO 13485 requirements into practical questions about human oversight, process validation, and who is qualified to make quality decisions.
They also write about the experience needed to lead a quality function, especially at a startup.
Cole connects regulatory requirements to the controls and people that make them work in practice.
In their discussion of an FDA warning letter involving AI-generated documents at a pharmaceutical manufacturer, they distinguish the drug-specific rule cited by FDA from the oversight and validation concerns that also matter in medical-device manufacturing.
They apply the same practical lens to automated inspection, pointing to validation, sampling, and calibration as safeguards, and to quality leadership: while an experienced manufacturing engineer may transition into Quality, leading the function calls for relevant competence and experience.
Cole makes one argument in several forms: putting AI into regulated manufacturing does not shift responsibility away from people.
Read more
They read FDA warning letters and ISO 13485 closely, then translate them into practical steps for manufacturers: review AI-generated documents before relying on them, validate automated inspection rather than trust it, and put someone demonstrably competent in charge of quality. The writing is short and specific, with each point grounded in the relevant clause, letter, or inspection practice.
AI can write the documents, but a qualified person still owns them
Cole's central point: AI agents may help produce specifications, procedures, and production records, but the manufacturer is accountable for their contents.
Read more
Qualified personnel, not the tool, must approve specifications and procedures.
In pharmaceutical manufacturing, 21 CFR 211.22(c) assigns the quality control unit responsibility for approving or rejecting specifications affecting identity, strength, quality, and purity.
They argue the same discipline applies to device makers through ISO 13485, under which various processes require review and approval by qualified personnel.
When an AI agent misses a legal requirement, the resulting noncompliance is the company's, not the agent's, to resolve.
In a warning letter dated 2 April 2026 to Purolea Cosmetics Lab, inspectors found the company used AI agents to create drug product specifications, procedures, and master production or control records, then treated the output as compliant without human review.
Asked why process validation had not been carried out before distribution, the company said it was unaware of the requirement because the AI agent never told it.
The FDA described this as overreliance on artificial intelligence.
Cole notes the facility stopped all production and had to justify why already-distributed product should not be recalled.
Cole says they do not normally comment on warning letters about pharmaceutical products, but this one matters to device-manufacturing readers because of its AI section. The focus is the AI failure mode, not the drug rule itself, which they say applies to device makers in parallel rather than directly.
Automated inspection is fine only with validation, guardrails, and a human backstop
Cole treats automation as a compliance question, not just an efficiency one.
Read more
Component inspection using electronic imaging and software can check far more parts than human inspectors, but a process not verified through later monitoring or measurement must be validated under ISO 13485 7.5.6.
They distinguish validation from verification, explain the condition that determines which is required, and identify the controls that keep a validated system trustworthy.
The organization remains responsible for whether the product meets specification, regardless of the automated system's conclusion.
Cole describes electronic imaging inspecting high volumes of parts, then identifies the safeguards needed even after validation: component sampling and inspection, plus periodic equipment calibration checks to ensure a drifting machine cannot pass defective product. The risk is equipment error slipping through a process everyone assumed was sound.
Quality leadership is a competence question that inspections actually test
Cole argues that appointing someone with no quality assurance background to lead Quality is a bad hire, especially in small start-ups where one person shapes the whole quality strategy.
Read more
The argument rests on ISO 13485 Section 6.2, which requires personnel doing work that affects product quality to be competent on the basis of appropriate education, training, skills, and experience. They also point to inspection practice: inspectors ask for the documentation that supports this competence requirement.
In inspections Cole has taken part in, one of the earliest requests was for a job description, a copy of the resume, and a description of the person's qualifications.
They distinguish a Quality Manager, who runs day-to-day operations, from a Head of Quality, who shapes quality strategy for years and keeps the whole management system effective.
For a start-up unable to fund a full-time hire, they suggest considering a qualified consultant for the role instead of making an inexperienced appointment.
Cole explicitly allows crossovers, so their objection is to inexperience, not an unusual background. They cite manufacturing engineers who moved into quality after years of manufacturing work, close involvement with QC teams on component inspection, development of test methods and equipment, writing QMS procedures and work instructions, and participation in multiple FDA and ISO inspections.
Cole takes a specific text—a regulator's letter or someone else's article—and works out what it means for device manufacturers, naming the applicable clause rather than offering general commentary.
Read more
When another writer's position enters their posts, they credit it and distinguish its limits from their own conclusion.
Cole recommends a Forbes article by Greg Pavlik, Executive Vice President, AI and Data Management Services at Oracle Cloud Infrastructure, about the future of work and human judgment in the AI age.
As they summarize it, Pavlik argues that the AI era is not about machines becoming more capable but about human judgment mattering more than ever; pattern recognition has limits, and managing AI agents calls for three practices: setting clear objectives and guardrails, monitoring outputs and intervening proactively, and capturing lessons from errors.
Cole applies that argument to AI use in medical device development and manufacturing, with the Purolea finding as a concrete example.
This is the question a newcomer is most likely to arrive with: does putting AI into regulated manufacturing actually trigger enforcement, and where does the line fall?
Read more
Start here for one concrete case where an AI tool produced a document and the manufacturer was still held responsible for it. The post also shows how Cole moves from a specific warning letter to the clause that applies to readers.
Cole walks through an FDA warning letter dated 2 April 2026 to Purolea Cosmetics Lab.
Inspectors found the company used AI agents to write drug product specifications, procedures, and master production and control records, then treated the generated documents as compliant without human review.
The FDA cited 21 CFR 211.22(c), which places approval of specifications and procedures on the quality control unit.
The detail they linger on is the company's own explanation: it said it was not aware process validation was required before distribution because the AI agent never told it so.
Production at the facility stopped, and the company had to argue why already-distributed product should not be recalled.
Cole widens the lesson beyond pharmaceuticals.
ISO 13485 requires qualified personnel to review and approve processes, and a device manufacturer using AI to make production-related decisions must either verify those outputs through later monitoring or validate the process under 7.5.6.
For brands planning a campaign
For a quality and regulatory compliance brief, this supports content about AI-assisted document generation and where human approval gates have to sit. The named citations (21 CFR 211.22(c), ISO 13485 7.5.6) give a technical post a concrete regulatory hook instead of a general warning about AI.
This shows how Cole handles other people's material.
Read more
Rather than only commenting on regulator documents, they take a general argument from a vendor executive, name the specific clause it maps onto, then add the practical safeguard that clause implies. A reader deciding whether to follow Cole gets their method in a single post.
Cole recommends a Forbes article by Greg Pavlik of Oracle Cloud Infrastructure, which argues that as machines get more capable, human judgment matters more, that pattern recognition has limits, and that managing AI agents calls for three practices: set clear objectives and guardrails, monitor outputs and intervene proactively, and capture lessons from errors.
Cole translates the argument into device manufacturing.
Automated component inspection using electronic imaging can check parts faster than people, but it must be validated under ISO 13485 7.5.6 unless it is verified by later monitoring.
Even a validated automated process needs added guardrails, such as component sampling and periodic calibration checks, so equipment drift does not let defective product pass.
Responsibility for conformance stays with the organization regardless of what the automation concludes.
For brands planning a campaign
Useful for brands selling inspection, automation, or AI oversight tools: Cole engages vendor-authored thought leadership and turns it into a manufacturing-specific control. A campaign angle could pair the general AI-judgment argument with validation and sampling requirements.
This shows what Cole thinks about quality staffing and where they draw the line on experience.
Read more
Start here if the people side of a compliance program matters more to you than document-level rules, or if you want to see how they handle a debate they partly disagree with rather than only explaining a regulation.
Cole reacts to two posts about device manufacturers putting people with no quality assurance background in charge of Quality.
They do not rule out crossovers: manufacturing engineers can move into quality successfully after years of close work with QC teams, developing test methods and equipment, writing QMS procedures and work instructions, and sitting through several FDA and ISO inspections.
What they reject is appointing someone with no quality experience who is described as terrified of the unknown going into an FDA inspection.
Cole cites ISO 13485 Section 6.2, which requires personnel doing work that affects product quality to be competent on the basis of education, training, skills, and experience.
In inspections they have taken part in, one of the earliest requests was their job description, a copy of their resume, and a description of their qualifications for the role.
The second post they discuss separates a Quality Manager from a Head of Quality who shapes quality strategy for years and keeps the whole system effective.
For small startups worried about the cost of a full-time hire, Cole suggests a qualified consultant in the role until a permanent position is supportable.
For brands planning a campaign
Offers a hiring and consulting angle on quality staffing: who should own a quality function before an inspection, and when a fractional or consultant arrangement is defensible for a small manufacturer.
AI oversight and human sign-off in regulated manufacturing
Cole works through a 2 April 2026 FDA warning letter to Purolea Cosmetics Lab, where a company used AI agents to write drug product specifications, procedures, and master production or control records.
Read more
The FDA called this overreliance on artificial intelligence and cited 21 CFR 211.22(c), which requires a quality control unit to approve or reject specifications and procedures affecting identity, strength, quality, and purity.
Cole highlights the company's reply that its AI agent never told it process validation was required, then extends the reasoning to device makers: AI-generated documents still need review by qualified personnel, and AI decisions tied to production must be verified through later monitoring or validated under ISO 13485 7.5.6.
In a separate post, they reinforce the point: pattern recognition has limits, and oversight practices for AI agents—clear objectives and guardrails, active monitoring, and capturing lessons from errors—apply directly to device development and manufacturing.
Cole reads a primary enforcement document, quotes the governing clause, and transfers the finding from pharmaceutical rules to device-manufacturing equivalents.
For brands planning a campaign
A campaign can ask Cole to turn AI-governance rules into concrete device-manufacturing practices: which decisions need human approval, what validation or verification evidence looks like, and how to build guardrails around AI agents used in documentation and process control.
Cole's recurring format is close commentary on FDA warning letters and the regulations behind them.
Read more
They open the Purolea letter by explaining why a pharmaceutical warning letter is relevant, walk through the inspector's findings in the letter's own words, and close with the consequence for the company: production halted and a case to make against recalling distributed product. A second post follows the same structure, starting from a Forbes article on human judgment in the AI age and landing on the same warning-letter finding.
Each piece anchors on an identifiable document—a warning letter or a named article—and extracts the specific clause or practice a manufacturer should act on, rather than offering general commentary.
For brands planning a campaign
This is a repeatable brand format: a regulatory explainer built from a real enforcement action, useful for reaching quality and regulatory staff who want the citation and consequence, not just the headline.
Validating automated inspection and production processes
Cole points to component inspection using electronic imaging and software processing, which can check high part volumes faster than human inspectors.
Read more
Such processes, they write, must be validated under ISO 13485 7.5.6 if they are not verified by subsequent monitoring or measurement.
Even when validated, they call for extra guardrails, including component sampling and inspection and periodic calibration checks, so defective product cannot pass automated inspection.
The manufacturer remains responsible for ensuring the product conforms to specification.
Cole separates validation from verification, specifies the condition that determines which is required, and names additional controls that keep an automated system trustworthy.
Cole's worked example is a drug-manufacturing warning letter; they explain that device requirements run in parallel through ISO 13485 rather than claiming the drug rule itself applies to device makers.
For brands planning a campaign
Useful for campaigns targeting manufacturers introducing automated inspection or machine-vision lines: Cole frames the compliance question around the evidence and controls a reviewer will expect.
Quality leadership competence and hiring the right head of Quality
Cole argues that a company hiring someone with no quality-assurance background to lead Quality has hired the wrong person, especially if the appointee at a start-up is described as terrified of the unknown before a pending FDA inspection.
Read more
They allow that transfers can work—they have seen manufacturing engineers move into quality successfully—but only after years of manufacturing experience, close work with QC teams on component inspection, test method and equipment development, procedure and work instruction writing, and participation in FDA and ISO inspections.
Cole cites ISO 13485 section 6.2 on personnel competence and the inspection routine of producing a job description, resume, and qualifications.
They distinguish the Quality Manager role from a Head of Quality role that shapes quality strategy for years, and suggest a qualified consultant for start-ups that cannot yet fund a full-time position.
Cole combines inspection practice and regulation: the standard states the competence requirement, and inspection experience shows how it is tested.
For brands planning a campaign
A campaign can position Cole on the talent and competency side of compliance: what a head of Quality needs to have done, how to demonstrate it to an inspector, and where a consultant fits before a full-time hire.
The LinkedIn posts do not state any brand, client, employer, sponsorship, or investment relationship for Mark Cole.
Read more
They discuss FDA warning letters, ISO 13485 requirements, and quality-leadership hiring; the companies and publications mentioned (a pharmaceutical manufacturer named in an April 2026 warning letter, Forbes, and Oracle Cloud Infrastructure) are cited as news subjects or outside authors, not as organizations they work with or promote. No commercial relationship is stated, so no relationship items are listed.
Cole writes short, citation-first posts about quality and regulatory compliance in medical device and pharmaceutical manufacturing.
Read more
Start with the post on a warning letter involving AI agents used to write drug specifications and procedures: it lays out the FDA's finding, the rule behind it, and why the same discipline applies to device makers through ISO 13485.
Posts on automated inspection and quality leadership hiring show the two habits that run through the writing: name the clause governing the decision, then say what a manufacturer should do differently.
To check the reasoning against the source text, keep ISO 13485 sections 6.2 and 7.5.6 and the cited regulation open; each post identifies the provision it addresses.
FDA warning lettersISO 13485AI oversight in regulated manufacturingRegulatory complianceValidation of automated inspectionMedical device quality managementQuality leadership hiringRegulatory explainerLinkedIn postsQuality and regulatory professionalsMedical device manufacturers
Pawel Olszowy
Both write short, framework-anchored explainers for people who run regulated manufacturing.
Read more
Each names a specific mechanism, describes it in plain terms, then translates it into action for a development or production team.
Olszowy covers ICH Q12's established conditions, change management protocols, and lifecycle document, as well as process analytical technology in API production.
Cole covers 21 CFR 211.22(c), ISO 13485 7.5.6, and AI-produced documents.
Both focus on the named tool and its practical consequences rather than generalities.
Olszowy focuses on pharmaceutical CMC and lifecycle regulation, looking ahead to how manufacturers can design flexibility into a product before approval.
Cole focuses on enforcement and device regulation: warning letters, inspection findings, quality leadership competence, and where an AI decision needs a human signature.
Olszowy writes from inside a manufacturer's regulatory function about how to build options; Cole writes about what a regulator has cited and what follows.
Both use a practical format: a short post built around a repeatable exercise readers can run themselves, not a general opinion.
Read more
Neuhart compares staffing at five locations, pairing high-turnover sites with well-performing ones and listing what to compare.
Cole walks through a warning letter clause by clause and ends with the step a manufacturer should take.
Both write for operations leaders in industrial workplaces and close with a concrete next action.
Neuhart covers contingent labor and workforce planning across food service, facilities, hospitality, and defense manufacturing, focusing on shifts, pay, transportation, and manager response.
Cole covers quality systems, regulator findings, and AI oversight in medical device and pharmaceutical manufacturing, focusing on standards and evidence.
Neuhart analyzes the site and its staffing pattern; Cole analyzes the regulation and the decision it governs.
Both turn a technical standard into an implementation or purchasing decision for a manufacturing audience.
Read more
Cacciatore tells readers to ask for the IEC 62443-4-2 certificate and explains what a certification level covers; Cole asks who signs off on AI-produced specifications and what validation evidence a reviewer will expect. Both write short posts with bold headlines for plant, engineering, and operations readers, using a real event as the hook rather than an abstract claim.
Cacciatore writes about industrial automation, robotics, and device-level cybersecurity, largely for Canadian manufacturers and defence supply chains, framing the opportunity around modernization and capability.
Cole writes about device and drug quality systems, inspections, and AI oversight, framing the issue around compliance and consequences.
Cacciatore's audience is deciding what to buy and connect; Cole's is deciding what to approve, validate, and staff.
Mark Cole’s three posts target people who run or staff quality and regulatory functions in medical device and pharmaceutical manufacturing: they quote ISO 13485 clauses, cite 21 CFR sections, and discuss FDA inspection expectations and AI oversight.
Read more
The content is relevant to compliance, quality assurance, and regulatory affairs practitioners rather than a general business audience.
The only measured audience figure available is 978 LinkedIn followers as of 9 October 2026; it does not show their job function, employer type, seniority, or geography.
Before placing this creator in a campaign aimed at quality or regulatory decision-makers, ask for an audience breakdown or survey covering employer type, job function, seniority, and country, plus recent performance figures for posts on comparable topics and depth, such as FDA warning letter analysis or ISO 13485 process validation.
Mark Cole's posts give a brand no partnership menu to work from.
Read more
The three posts are practitioner commentary on quality and regulatory compliance in medical device and pharmaceutical manufacturing: FDA warning letters, ISO 13485 requirements, AI oversight of documents and production decisions, and the case for experienced quality leadership.
None contains a sponsored segment, a paid brand mention, an affiliate link, or any stated commercial offer, and no sponsor relationship is disclosed.
No media kit, rate card, sponsorship policy, or partnership inquiry route appears in the posts.
Ask directly about availability, rates, and partnership terms.
The LinkedIn account shows roughly 978 followers as of October 2026, a small audience relative to the depth of the technical commentary — relevant if a plan depends on reach rather than demonstrated compliance expertise.
Strong fit on subject-matter credibility, with limits on reach and commercial mechanics.
Read more
Brief
A medical device manufacturer wants to strengthen its quality and regulatory compliance program, prepare for FDA inspection, and govern AI use in production documentation and automated inspection.
Reasons
Mark Cole's posts engage directly with the problems a campaign on these topics would address: FDA warning letters, ISO 13485 requirements, AI-generated compliance documents, validation of automated inspection, and quality-leadership competence.
The work section shows a repeatable teaching method: take a real enforcement document or vendor argument, quote the governing clause, and translate it into device-manufacturing practice. That approach suits a compliance program that needs practical explanation, not slogans.
Usable material includes the 2 April 2026 Purolea Cosmetics Lab warning letter, 21 CFR 211.22(c), ISO 13485 7.5.6 on process validation, ISO 13485 Section 6.2 on personnel competence, and the argument that responsibility for conformance stays with the manufacturer even when automation or AI makes a call.
The only published audience figure is 978 LinkedIn followers as of 9 October 2026; no demographic or performance data is published. The partnerships section lists no media kit, rate card, sponsorship policy, or inquiry route. Before committing, ask for audience and performance data, rates, and a direct inquiry route. This supports an expert-led pilot or direct scoping conversation, not a broad-reach buy.
Use this creator when the goal is qualified technical credibility among quality, regulatory, and manufacturing teams. Do not treat the follower count as evidence of buyer reach or job function.
When to choose a specialist
Poor fit.
Read more
Brief
A direct-to-consumer wellness brand or general AI productivity brand wants large-scale awareness and direct response among non-specialist consumers or broad business buyers.
Reasons
The posts are narrow and technical, written for people who recognize ISO 13485 clauses and 21 CFR citations rather than general consumers or business audiences.
The posts show no lifestyle content, product-review formats, affiliate links, sponsored segments, or commercial offer. The partnerships section records an empty formats array and no inquiry route. Ask how a paid consumer campaign would be executed.
The only published audience figure is 978 LinkedIn followers as of 9 October 2026. No platform demographic, survey, or post-performance data is published, so reach, conversion, geography, seniority, and employer type cannot be assessed. Ask for these data before promising campaign outcomes.
A campaign that depends on broad reach or impulse response is mismatched with the information published here. This creator's material is strongest when explaining a regulated process to quality and regulatory staff.
A worked campaign example
Angle
Put human approval back into the use of AI: show where AI can help, where a qualified person must sign off, and what documentation an FDA or ISO reviewer will expect.
Brief
The same medical device manufacturer as the good-fit brief, with a narrower focus on launching machine-vision inspection and AI-assisted document generation.
Measurement
Because no audience or post-performance data is published, start with a pilot and collect first-party data. Measure saves and comments from quality, regulatory, and manufacturing roles; requests for the checklist or a follow-up discussion; and whether the internal team can apply the validation and sign-off distinctions after reading. Do not judge the pilot by raw impressions or follower growth. Ask directly about commercial formats and an inquiry route before scoping a paid arrangement.
Sequence
Asset 1, warning-letter teardown: walk through the Purolea Cosmetics Lab letter. The FDA found the company used AI agents to create drug product specifications, procedures, and master production or control records, then treated the output as compliant. The company said its AI agent never told it that process validation was required. Explain the cited rule, 21 CFR 211.22(c), and why an AI tool does not carry the quality unit's approval responsibility.
Asset 2, device-manufacturing translation: map the same logic onto ISO 13485 7.5.6. If an automated inspection or AI-influenced production decision is not verified by later monitoring or measurement, the process must be validated. Add the guardrails Mark Cole names: component sampling and inspection, plus periodic calibration checks, so defective product cannot pass. Close with the point that conformance responsibility stays with the organization.
Asset 3, inspection-readiness and staffing: use ISO 13485 Section 6.2 to explain what an inspector may ask for, including a job description, resume, and evidence of qualifications. Contrast a Quality Manager role with a Head of Quality who shapes strategy, and note the consultant option for a start-up that cannot yet fund a full-time hire.
Why it works
Each asset starts from details in Mark Cole's posts: a real warning letter, named clauses, and a practical manufacturing problem. They do not ask Mark to become a general AI commentator.
The sequence gives the buyer three useful outputs: a concrete enforcement example, a validation and guardrail checklist in prose, and an inspection-readiness conversation about who is qualified to sign off.
The angle matches the stated reader brief by drawing directly on expertise in FDA inspection, ISO 13485, and AI validation. It is a content or advisory pilot, not a reach play.
Choose Pawel Olszowy when a compliance task sits in pharmaceutical or small-molecule manufacturing rather than a medical device quality system.
Read more
The posts show clause-and-tool-level work on ICH Q12 lifecycle management: Established Conditions that distinguish dossier elements critical to product quality from those manageable through the Pharmaceutical Quality System; Post-Approval Change Management Protocols agreed with regulators in advance; and a Product Lifecycle Management document treated as a living roadmap.
A second post covers Process Analytical Technology as more than instruments: validated analytical models, integration with LIMS and MES, and cross-functional ownership across R&D, manufacturing, and QA, with real-time monitoring of critical quality attributes during synthesis, granulation, and tableting.
If the manufacturer needs to plan a second site, a new supplier, higher volumes, or a process change without a lengthy CMC exercise, this material addresses the decision more directly than Mark Cole's device-focused posts.
Olszowy focuses on pharmaceutical regulation, not medical devices: there is no ISO 13485, FDA inspection preparation, or device-specific guidance on who must approve AI-generated documents or how to validate automated inspection.
The regulatory frame is ICH Q12, CMC dossiers, and post-approval variation strategy.
A device manufacturer choosing Olszowy gets a stronger model for designing future change into a product early and implementing PAT, but still needs the device quality-system and enforcement material Cole supplies.
The comparison rests on two posts; ask for more examples before judging the breadth of the work.
Choose Josh Neuhart when a compliance program is failing on people rather than procedure.
Read more
The posts offer two repeatable workforce exercises.
The first starts with a multi-site staffing problem: if 8 of 200 locations keep asking for help, that is 8 local problems, not a national labor shortage.
Neuhart pairs each high-turnover location with a similar well-performing one and compares pay competitiveness within a 10-mile radius, shift times, transportation access for a 5:00 AM start, hiring speed, manager response time, and what happens in a new hire's first week.
The second applies the same logic to defense manufacturing: identify who cannot take a week off without risking a delivery, then check who is qualified and authorized for each critical task on the scheduled shift, whether a qualified backup exists, and whether that backup would leave another critical operation uncovered.
This question set is useful when a quality unit is fully staffed on paper but a required inspection or sign-off depends on one qualified person.
Neuhart says nothing about ISO 13485, 21 CFR, validation of automated inspection, or oversight of AI-generated records.
Neuhart writes from a staffing-supplier perspective, offering to look at anonymized turnover data and inviting a message about contingent labor coverage, so the content is oriented to recruiting and workforce planning rather than to what an FDA investigator will ask for.
For a need to assess regulatory compliance and quality-system governance, Neuhart is the sharper read only for the staffing slice that Cole raises but does not develop.
Choose Anthony Cacciatore when the decision has moved from the quality system to equipment and its connections.
Read more
One post argues that cybersecurity now belongs in robot selection alongside payload, reach, accuracy, cycle time, price, service, and integration.
Robot controllers talk to PLCs and HMIs, connect to MES and ERP, feed cloud platforms, and allow remote access.
The post explains IEC 62443-4-2 and Security Level 2 in plain terms, distinguishes a manufacturer's claim that a product is cyber-secure from independent certification, and tells buyers to ask the manufacturer, the integrator, and for the certificate.
A second post frames increased Canadian defence spending as a manufacturing modernization opportunity: traceability, quality control, cybersecurity, production consistency, and scalability requirements will push suppliers toward automation.
The argument is that the measure of the investment should be what Canada builds as well as what it buys.
If the campaign is about the automation roadmap, connected-factory purchasing, or the defence supply chain rather than the compliance document trail, Cacciatore is closer to the subject.
Cacciatore focuses on automation and industrial cybersecurity, not quality-system oversight or regulatory approval.
There is no ISO 13485 validation argument, FDA enforcement example, or guidance on who inside the organization must approve a production decision.
Choosing Cacciatore brings a stronger frame for automation and industrial cybersecurity, including which certifications to demand at purchase, but the manufacturer still needs Cole's material on validation, qualified sign-off, and the organization's continuing responsibility for conformance.
Ask for more examples before judging the breadth of Cacciatore's work; the posts here number two.
Mark Cole's LinkedIn posts cover FDA warning letters and the use of AI in regulated manufacturing, including a letter dated 2 April 2026 to Purolea Cosmetics Lab that cites 21 CFR 211.22(c), and a discussion of a Forbes article by Greg Pavlik of Oracle Cloud Infrastructure.
Another post covers quality leadership hiring and the competence requirement in ISO 13485 Section 6.2.
The ideas, work, topics, and similar-creator sections draw on these posts, and the similar-creator comparisons use posts by three other writers in regulated and industrial manufacturing.
The posts here do not carry publication dates, so no posting timeline is claimed.
No longer-form writing, video, podcasts, or transcripts appear here.
No audience demographics, post-performance data, media kit, or sponsorship terms appear here.
Reach and commercial mechanics are therefore left as open questions rather than described.
The posts are presented as Mark Cole's own writing, and employers, credentials, and any commercial relationships are not verified beyond what the posts themselves state.